Lyra Therapeutics LYRA 深 滬
已收盤 09-12 16:00:00 美东时间
6.29
-0.040
-0.63%
華盛通- 最 高6.72
- 今 開6.34
- 成交量 6.59万股
- 最 低 6.15
- 昨 收 6.33
- 總市值 1034.39万
- 52周最高 37.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.10
- 委 比 21.58%
- 總股本 164.45万
- 歷史最高 1100.00
- 量 比 3.55
- 振 幅 9.00%
- 歷史最低 4.10
- 每 手 1
- 風險率 2.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds
Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, congestion, and need for surgery.
09-03 00:33
Lyra Therapeutics Receives Nasdaq Deficiency Letter
An update from Lyra Therapeutics ( ($LYRA) ) is now available. On August 20, 20...
08-23 04:53
Lyra Therapeutics Q2 EPS $(5.51) Beats $(6.02) Estimate, Sales $183.000K Beat $171.250K Estimate
Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(5.51) per share which beat the analyst consensus estimate of $(6.02) by 8.47 percent. This is a 85.01 percent increase over losses of $(36.76) per share from
08-13 04:19
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Lyra Therapeutics announced strong Phase 3 results for LYR-210 in chronic rhinosinusitis (CRS), enabling business momentum and securing $5 million financing extending cash runway into Q3 2026. The ENLIGHTEN 2 trial met primary and secondary endpoints, with LYR-210 showing significant symptom improvement and safety. The company resumed manufacturing, engaged FDA discussions, and adjusted stock split to regain compliance. Second-quarter financials ...
08-12 20:01
Lyra Therapeutics registers shares for resale from warrant exercises
Lyra Therapeutics (NASDAQ:LYRA) registers 846,744 shares of common stock for resale by selling securityholders. Shares are issuable upon exercise of outstanding warrants; company will receive proceeds...
07-23 05:46
Lyra Therapeutics Secures $4.3M in Direct Offering
Lyra Therapeutics ( ($LYRA) ) just unveiled an update. On June 26, 2025, Lyra T...
06-27 22:59
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Lyra Therapeutics announced a registered direct offering of 423,372 common shares priced at $11.81 each, along with a concurrent private placement of warrants for up to 846,744 shares with an exercise price of $11.56. The initial gross proceeds are $5.0 million, with the potential for an additional $9.8 million from warrant exercises. Proceeds will be used for working capital, clinical development, and pre-commercialization of LYR-210. The offeri...
06-27 12:00
Primaris REIT to acquire Lime Ridge Mall for $416M
Primaris REIT (PMZ.UN:CA) will acquire 100% interest in Lime Ridge Mall in Hamilton, Ontario from Cadillac Fairview for $416M. The purchase will be funded with $235M in cash, $81M in REIT Units at $21...
06-17 04:30
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
